|
Hikma Pharmaceuticals PLC on Thursday unveiled new medium-term guidance forecasting high single-digit revenue and operating profit growth in the three years to 2027. The London-based pharmaceutical group expects compound annual revenue growth of 6% to 8% in the three years to 2027 with core operating profit growth of 7% to 9% over the three-year time frame to 2027. In 2024, Hikma reported revenue of $3.13 billion and core operating profit of $719 million. In April, Hikma said it expected revenue to grow by 4% to 6% in 2025 and for core operating profit to be in the range of $730 million to $770 million, would be growth of 4.3% at the mid-point. In addition, Hikma is introducing a five-year target for revenue to reach $5 billion by 2030. Hikma also announced that its Generics business is being renamed Hikma Rx to reflect its focus on providing differentiated and complex prescription (Rx) medicines. In response, shares in Hikma jumped 6.3% to 2,064.00 pence each in London on Thursday. Hikma provided the new outlook ahead of a presentation on Thursday to sell-side analysts and investors at its US manufacturing and R&D facility in Columbus, Ohio. The senior leadership teams from Hikma’s Generics and Injectables segments will present on their respective businesses, strategies, and plans to deliver long-term, sustainable growth, the firm said. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
